Objectives Advanced therapy medicinal products (ATMPs) are highly innovative therapies.
Their costs and uncertain value claims have raised concerns among health technology …

Background Advanced therapy medicinal products (ATMPs) are beginning to reach
European markets, and questions are being asked about their value for patients and how …

Background Advanced therapy medicinal products (ATMPs) represent an important
cornerstone for innovation in healthcare. However, uncertainty on the value, the high …

Objectives: We explore how broader aspects of a treatment's value and the impact of the
condition on patients not captured by routine health technology assessment (HTA) methods …

This review discusses the methodological challenges to the evaluation of advanced therapy
medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence …

Advanced therapy medicinal products (ATMPs) are a heterogeneous class of medicinal
products that by offering the potential of cure represent a paradigm shift in the approach of …

Background There is much interest from stakeholders in understanding how health
technology assessment (HTA) committees make national funding decisions for health …

Objectives The uncertainty in the cost-benefit of advanced therapy medicinal products
(ATMPs) is a current challenge for their reimbursement in health systems. This study aimed …

Background Health-technology assessment (HTA) plays an important role in informing drug-
reimbursement decision-making in many countries. HTA processes for the Pharmaceutical …

Objectives: We compared Polish and Scottish Health Technology Assessment (HTA)
process in order to elicit recommendations for future development of HTA methodological …